SLFN11 and cancer: In 2012, we discovered that SLFN11 is a dominant predictor of response to replication damaging agents widely used in cancer chemotherapy including TOP inhibitors, nucleoside analogues, platinum-based, and alkylating agents [118] (Table 1).